Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
BACKGROUND: More smokers report using e-cigarettes to help them quit than FDA-approved pharmacotherapy. OBJECTIVE: To assess the association of e-cigarettes with future abstinence from cigarette and tobacco use. DESIGN: Cohort study of US sample, with annual follow-up. PARTICIPANTS: US adult (ages 18+) daily cigarette smokers identified at Wave 1 (W1; 2013-14) of the PATH Study, who reported a quit attempt before W2 and completed W3 (n = 2443). EXPOSURES: Use of e-cigarettes, pharmacotherapy (including nicotine replacement therapy), or no product for last quit attempt (LQA), and current daily e-cigarette use at W2. ANALYSIS: Propensity score matching (PSM) of groups using different methods to quit. OUTCOME MEASURES: 12+ months abstinence at W3 from cigarettes and from all tobacco (including e-cigarettes). 30+ days abstinence at W3 was a secondary outcome. RESULTS: Among daily smokers with an LQA, 23.5% used e-cigarettes, 19.3% used pharmacotherapy only (including NRT) and 57.2% used no product. Cigarette abstinence for 12+ months at W3 was ~10% in each group. Half of the cigarette abstainers in the e-cigarette group were using e-cigarettes at W3. Different methods to help quitting had statistically comparable 12+ month cigarette abstinence at W3 (e-cigarettes vs no product: Risk Difference (RD) = 0.01, 95% CI: -0.04 to 0.06; e-cigarettes vs pharmacotherapy: RD = 0.02, 95% CI:-0.04 to 0.09). Likewise, daily e-cigarette users at W2 did not show a cessation benefit over comparable no-e-cigarette users and this finding was robust to sensitivity analyses. Abstinence for 30+ days at W3 was also similar across products. LIMITATIONS: The frequency of e-cigarette use during the LQA was not assessed, nor was it possible to assess continuous abstinence from the LQA. CONCLUSION: Among US daily smokers who quit cigarettes in 2014-15, use of e-cigarettes in that attempt compared to approved cessation aids or no products showed similar abstinence rates 1-2 years later.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kalkhoran, S., & Glantz, S. A. (2016) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(15)00521-4 · Cited by 895
Design and methods of the Population Assessment of Tobacco and Health (PATH) Study
Hyland, A., Ambrose, B. K., Conway, K. P., Borek, N., Lambert, E., Carusi, C., Taylor, K., Crosse, S., Fong, G. T., Cummings, K. M., et al. (2017) · Tobacco Control · doi:10.1136/tobaccocontrol-2016-052934 · Cited by 872 · cited 2×
“The Population Assessment of Tobacco and Health (PATH) Study [12] is a large, nationally representative longitudinal study that collects detailed measures of tobacco use and related information annually.”
BackgroundMethodSelf-citationDennis, M. L., Chan, Y., & Funk, R. R. (2006) · The American Journal on Addictions · doi:10.1080/10550490601006055 · Cited by 509 · cited 1×
“Briefly, these included sociodemographic variables, cigarette smoking history, nicotine dependence [23], quitting history, timing of LQA, relative perceived harm (cigarettes, e-cigarettes), social variables (smoke-free home, exposure to other smokers), and other covariates (symptoms for externalizing and internalizing…”
BackgroundTime-dependent bias was common in survival analyses published in leading clinical journals
van Walraven, C., Davis, D., Forster, A. J., & Wells, G. A. (2004) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2003.12.008 · Cited by 337 · cited 1×
“However, this group excludes many quitters who relapsed between the LQA and W2, and thus stopped using e-cigarettes daily, potentially leading to an upward bias [17] in the observed cessation at W2.”
BackgroundElectronic cigarettes for smoking cessation
Hartmann-Boyce, J., McRobbie, H., Lindson, N., Bullen, C., Begh, R., Theodoulou, A., Notley, C., Rigotti, N., Turner, T., Butler, A., et al. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010216.pub · Cited by 179
Quit Methods Used by US Adult Cigarette Smokers, 2014–2016
Caraballo, R. S., Shafer, P. R., Patel, D., Davis, K. C., & McAfee, T. A. (2017) · Preventing Chronic Disease · doi:10.5888/pcd14.160600 · Cited by 177
Cited by
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
(2022) · PubMed Central · doi:10.6515/acs.202205_38(3).20220321a · Cited by 117
The Potential Impact of Widespread Cessation Treatment for Smokers With Depression
Tam, J., Warner, K. E., Zivin, K., Taylor, G. M. J., & Meza, R. (2021) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2021.04.024 · Cited by 7
Metadata
- Authors
- Pierce, J. P., Benmarhnia, T., Chen, R., White, M., Abrams, D. B., Ambrose, B. K., Blanco, C., Borek, N., Choi, K., Coleman, B., Compton, W. M., Cummings, K. M., Delnevo, C. D., Elton-Marshall, T., Goniewicz, M. L., Gravely, S., Fong, G. T., Hatsukami, D., Henrie, J., Kasza, K. A., Kealey, S., Kimmel, H. L., Limpert, J., Niaura, R. S., Ramôa, C., Sharma, E., Silveira, M. L., Stanton, C. A., Steinberg, M. B., Taylor, E., Bansal-Travers, M., Trinidad, D. R., Gardner, L. D., Hyland, A., Soneji, S., & Messer, K.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2020-09-02
- Volume
- 15
- Issue
- 9
- Pages
- e0237938
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W3082235822
- Cited by
- 72
- References
- 6
- FWCI
- 6.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. https://app.cochat.ai/papers/10.1371/journal.pone.0237938
- The paper
- Pierce, J. P., Benmarhnia, T., Chen, R., White, M., Abrams, D. B., Ambrose, B. K., Blanco, C., Borek, N., Choi, K., Coleman, B., Compton, W. M., Cummings, K. M., Delnevo, C. D., Elton-Marshall, T., Goniewicz, M. L., Gravely, S., Fong, G. T., Hatsukami, D., Henrie, J., . . . Messer, K. (2020). Role of e-cigarettes and pharmacotherapy during attempts to quit cigarette smoking: The PATH Study 2013-16. PLOS ONE. https://doi.org/10.1371/journal.pone.0237938
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.